Claims

1. Liquid pharmaceutical composition comprising a polypeptide, TRIS and phosphate, the polypeptide comprising the amino acid sequence reproduced in SEQ ID NO: 8, characterized in

that the composition contains the polypeptide in a concentration of from 0.5 µg/ml to 3.0 mg/ml,

that the composition contains 100 mM TRIS and 50 mM phosphate,

that the pH of the composition is about 6.0 and

that the composition contains 0.04% polysorbate 80.

2. Composition according to Claim 1, characterized in that the composition additionally contains a lyoprotectant.

3. Composition according to Claim 2, characterized in that the composition contains 2 - 10% of a lyoprotectant.

4. Composition according to either of Claims 2 and 3, characterized in that the lyoprotectant is trehalose or trehalose dihydrate.

5. Composition according to Claim 1, characterized in that the composition additionally contains about 4% trehalose dihydrate.

6. Composition according to any of the preceding claims, characterized in that the composition contains the polypeptide in a concentration of 2 mg/ml.

7. Solids mixture obtainable by lyophilization of a liquid composition according to any of the preceding claims.

8. Liquid pharmaceutical composition, characterized in that the composition is reconstituted by dissolving a lyophilized solids mixture according to claim 6 in a suitable liquid medium.

9. Composition according to any of the preceding claims, characterized in that the bioavailability of the polypeptide following subcutaneous administration of the composition is >60%.

10. Composition according to any of the preceding claims for use in ~~a therapeutic method~~therapy.

11. Composition according to any of the preceding claims for use in ~~a therapeutic method~~therapy, said ~~method~~ therapy comprising parenteral administration of the composition.

12. Composition according to any of the preceding claims for use in ~~a method for therapeutically treating~~ the treatment of hyper-proliferative diseases of the prostate.

13. Composition according to any of the preceding claims for use in ~~a method for therapeutically treating~~the treatment of hyper-proliferative diseases of the prostate, the ~~method~~ treatment comprising subcutaneous administration of the composition.

14. Syringe containing a composition according to any of the preceding claims.